Gene expression signatures for colorectal cancer microsatellite status and HNPCC

被引:65
作者
Kruhoffer, M
Jensen, JL
Laiho, P
Dyrskjot, L
Salovaara, R
Arango, D
Birkenkamp-Demtroder, K
Sorensen, FB
Christensen, LL
Buhl, L
Mecklin, JP
Järvinen, H
Thykjaer, T
Wikman, FP
Bech-Knudsen, F
Juhola, M
Nupponen, NN
Laurberg, S
Andersen, CL
Aaltonen, LA
Orntoft, TF
机构
[1] Aarhus Univ Hosp, Dept Clin Biochem, Mol Diagnost Lab, DK-8200 Aarhus, Denmark
[2] Univ Aarhus, Dept Stat, Aarhus, Denmark
[3] Univ Helsinki, Dept Med Genet, Haartman Inst, Helsinki, Finland
[4] Aarhus Univ Hosp, Inst Pathol, DK-8200 Aarhus, Denmark
[5] Jyvaskyla Cent Hosp, Dept Pathol, Helsinki, Finland
[6] Univ Helsinki, Haartman Inst, Univ Cent Hosp, Helsinki, Finland
[7] AROS Appl Biotechnol ApS, Res Pk Skejby, Aarhus, Denmark
[8] Aarhus Univ Hosp, Dept Surg, DK-8200 Aarhus, Denmark
关键词
colon cancer; gene expression; microsatellite instability; HNPCC;
D O I
10.1038/sj.bjc.6602621
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The majority of microsatellite instable (MSI) colorectal cancers are sporadic, but a subset belongs to the syndrome hereditary nonpolyposis colorectal cancer (HNPCC). Microsatellite instability is caused by dysfunction of the mismatch repair (MMR) system that leads to a mutator phenotype, and MSI is correlated to prognosis and response to chemotherapy. Gene expression signatures as predictive markers are being developed for many cancers, and the identification of a signature for MMR deficiency would be of interest both clinically and biologically. To address this issue, we profiled the gene expression of 101 stage II and III colorectal cancers ( 34 MSI, 67 microsatellite stable (MSS)) using high-density oligonucleotide microarrays. From these data, we constructed a nine-gene signature capable of separating the mismatch repair proficient and deficient tumours. Subsequently, we demonstrated the robustness of the signature by transferring it to a real-time RT-PCR platform. Using this platform, the signature was validated on an independent test set consisting of 47 tumours ( 10 MSI, 37 MSS), of which 45 were correctly classified. In a second step, we constructed a signature capable of separating MMR-deficient tumours into sporadic MSI and HNPCC cases, and validated this by a mathematical cross-validation approach. The demonstration that this two-step classification approach can identify MSI as well as HNPCC cases merits further gene expression studies to identify prognostic signatures.
引用
收藏
页码:2240 / 2248
页数:9
相关论文
共 36 条
[1]  
Allegra CJ, 2003, NEW ENGL J MED, V349, P1774
[2]   Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays [J].
Alon, U ;
Barkai, N ;
Notterman, DA ;
Gish, K ;
Ybarra, S ;
Mack, D ;
Levine, AJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) :6745-6750
[3]   Normalization of real-time quantitative reverse transcription-PCR data: A model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets [J].
Andersen, CL ;
Jensen, JL ;
Orntoft, TF .
CANCER RESEARCH, 2004, 64 (15) :5245-5250
[4]   Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity [J].
Banerjea, Ayan ;
Ahmed, Shafi ;
Hands, Rebecca E. ;
Huang, Fei ;
Han, Xia ;
Shaw, Peter M. ;
Feakins, Roger ;
Bustin, Stephen A. ;
Dorudi, Sina .
MOLECULAR CANCER, 2004, 3 (1)
[5]  
Birkenkamp-Demtroder K, 2002, CANCER RES, V62, P4352
[6]   A comparison of normalization methods for high density oligonucleotide array data based on variance and bias [J].
Bolstad, BM ;
Irizarry, RA ;
Åstrand, M ;
Speed, TP .
BIOINFORMATICS, 2003, 19 (02) :185-193
[7]   Hereditary nonpolyposis colorectal cancer - molecular basis [J].
Brezden-Masley, C ;
Aronson, MD ;
Bapat, B ;
Pollett, A ;
Gryfe, R ;
Reston, M ;
Gallinger, S .
SURGERY, 2003, 134 (01) :29-33
[8]  
Bubb VJ, 1996, ONCOGENE, V12, P2641
[9]   Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer [J].
Cappel, WHDN ;
Meulenbeld, HJ ;
Kleibeuker, JH ;
Nagengast, FM ;
Menko, FH ;
Griffioen, G ;
Cats, A ;
Morreau, H ;
Gelderblom, H ;
Vasen, HFA .
INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (03) :468-471
[10]   Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer [J].
Cunningham, D ;
Pyrhönen, S ;
James, RD ;
Punt, CJA ;
Hickish, TF ;
Heikkila, R ;
Johannesen, TB ;
Starkhammar, H ;
Topham, CA ;
Awad, L ;
Jacques, C ;
Herait, P .
LANCET, 1998, 352 (9138) :1413-1418